Reducing injection burden has long been a priority in diabetes care. Now, a weekly, fixed-dose combination of basal insulin and a GLP-1 receptor agonist is one step closer to approval in Europe.
BAGSVÆRD, Denmark and PLAINSBORO, N.J., Sept. 29, 2025 /PRNewswire/ -- Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration ...
Wegovy (semaglutide) is a once-weekly injection that was first approved in 2017 to help with weight loss and lower the risk of heart problems. Now, the FDA has approved it to treat a liver condition ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Insulin efsitora was noninferior to once-daily insulins ...
"Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 ...
With detailed readouts from a suite of late-stage trials now on tap, Eli Lilly is heading to regulators in pursuit of a green light for its once-a-week insulin asset efsitora alfa. Lilly on Sunday ...
NDTV Profit on MSN
Ozempic launched in India for type 2 diabetes treatment: Check cost, should you take it for weight loss?
Ozempic (injectable semaglutide) is a once-weekly treatment indicated as an add-on to diet and exercise for adults with uncontrolled Type 2 diabetes mellitus (T2DM).
Below is a comparison of today’s most prescribed GLP-1 medications, including Ozempic and Trulicity, both widely used for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback